ODE Looks To FY 2002 Budget To Fill Vacancies Left By Departing Staff
This article was originally published in The Gray Sheet
Executive Summary
The Office of Device Evaluation hopes that a higher payroll allocation in the fiscal year 2002 budget will allow it to fill a number of positions that have opened up as staffers either retire or switch to the private sector.
You may also be interested in...
FDA Aims For Greater Efficiency Under Modular PMA Revamp
FDA wants to limit the number of premarket components sponsors can submit under its modular PMA program in order to ensure efficient use of its device review resources.
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.